This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MCI-Framingham | |
|---|---|
| Name | MCI-Framingham |
MCI-Framingham is a prognostic instrument originating from longitudinal cohort research designed to estimate risk trajectories for mild cognitive impairment progression and related outcomes. It synthesizes demographic, clinical, and biomarker inputs to produce individualized risk estimates used in clinical research and practice. The instrument has been discussed in the context of neuroepidemiology, translational neurology, and health services research.
MCI-Framingham was developed to quantify transition probabilities among cognitive states drawing on datasets from cohort studies such as the Framingham Heart Study, Rotterdam Study, Cardiovascular Health Study, Alzheimer's Disease Neuroimaging Initiative, and National Institute on Aging cohorts. Influences include methodologies from Johns Hopkins University, Massachusetts General Hospital, Harvard Medical School, Mayo Clinic, and Columbia University research groups. The tool integrates predictors similar to those used in risk models like the Framingham Risk Score, CHA2DS2-VASc score, QRISK, APACHE II, and SCORE (risk model), while aligning with diagnostic criteria from DSM-IV, DSM-5, NINCDS-ADRDA, National Institute on Aging-Alzheimer's Association guidelines, and staging frameworks employed by Clinical Dementia Rating investigators.
Development borrowed statistical techniques from studies at University College London, Stanford University, University of Cambridge, University of Oxford, and Imperial College London. Predictor selection referenced biomarkers characterized by groups at Johns Hopkins Hospital, University of California, San Francisco, Washington University in St. Louis, and University of Pennsylvania including cerebrospinal fluid markers validated by Mayo Clinic Jacksonville and neuroimaging metrics validated in consortia like ENIGMA and ADNI. Survival analysis methods invoked work by researchers affiliated with Nuffield Department of Population Health, Karolinska Institutet, Karolinska University Hospital, Max Planck Society, and University of Melbourne. Variable harmonization used protocols from World Health Organization, International Working Group on MCI, and measurement standards promulgated by National Institutes of Health, European Medicines Agency, Food and Drug Administration, and Global Alzheimer's Platform Foundation.
External validation cohorts included samples assembled by Alzheimer Europe, Alzheimer's Association, Canadian Study of Health and Aging, Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing, Baltimore Longitudinal Study of Aging, and Rotterdam Study investigators. Performance metrics were compared to algorithms from DeepMind, Google Health, IBM Watson Health, Microsoft Research, and academic groups at Princeton University and Yale University. Calibration and discrimination analyses referenced methods used by teams at University of Toronto, McGill University, University of British Columbia, Seoul National University Hospital, and Peking University Health Science Center. Reporting standards aligned with TRIPOD Statement, STARD, CONSORT, and recommendations from Cochrane Collaboration reviewers.
Clinical uptake has been explored in settings affiliated with Veterans Affairs, National Health Service, Kaiser Permanente, Cleveland Clinic, and Johns Hopkins Medicine. Applications include stratification in trials conducted by Biogen, Eli Lilly and Company, Roche, Novartis, and AstraZeneca, and secondary analyses for devices by Medtronic and GE Healthcare. Research translations have been piloted in memory clinics at Mount Sinai Hospital, Cedars-Sinai Medical Center, Brigham and Women's Hospital, Toronto General Hospital, and community programs supported by Alzheimer's Society (UK), Alzheimer Society of Canada, and Dementia Australia. Implementation tools drew on electronic health record integrations developed by Epic Systems Corporation, Cerner Corporation, and analytics platforms from SAS Institute and RStudio.
Critiques paralleled those leveled at prognostic models in studies from The Lancet, JAMA, New England Journal of Medicine, BMJ, and specialty journals such as Neurology (journal), Alzheimer's & Dementia, and Journal of Alzheimer's Disease. Concerns included cohort representativeness raised by investigators at University of Cape Town, University of Nairobi, University of São Paulo, Instituto Nacional de Salud Pública (Mexico), and All India Institute of Medical Sciences. Ethical, regulatory, and equity issues echoed discussions from World Health Organization, UNESCO, European Commission, National Academy of Medicine, and Institute of Medicine. Methodological debates referenced work by scholars at Princeton University, Columbia University Mailman School of Public Health, Johns Hopkins Bloomberg School of Public Health, and Harvard T.H. Chan School of Public Health.
The model's lineage traces through landmark cohort studies like Framingham Heart Study, Dunedin Multidisciplinary Health and Development Study, Whitehall Study, British Regional Heart Study, and population efforts such as UK Biobank and Million Veteran Program. Influential investigators and institutions include Ancel Keys, Willem Einthoven, Arno Motulsky, Denis Burkitt, Alfred Blalock, Rosalyn Yalow, Stanley Prusiner, Rita Levi-Montalcini, Paul Lauterbur, Peter Mansfield, Harvey Cushing, Viktor Hamburger, Dorothy Hodgkin, Alexander Fleming, Louis Pasteur, Robert Koch, Isaac Newton, Charles Darwin, Albert Einstein, Marie Curie, Niels Bohr, Jonas Salk, Edward Jenner, Sigmund Freud, Carl Jung, Gregor Mendel, James Watson, Francis Crick, Rosalind Franklin, Barbara McClintock, Max Delbrück, Linus Pauling, Richard Feynman, Michael Faraday, Galileo Galilei, Johannes Kepler, Antonie van Leeuwenhoek, Louis Pasteur, Alfred Nobel, Alexander Fleming, Thomas Edison, Nikola Tesla, Guglielmo Marconi, Ada Lovelace, Alan Turing, Grace Hopper, John von Neumann, Katherine Johnson, Srinivasa Ramanujan, Emmy Noether, Évariste Galois, Henri Poincaré, Carl Friedrich Gauss, Leonhard Euler, Blaise Pascal, Euclid, Pythagoras—reflecting the cross-disciplinary heritage informing contemporary prognostic modeling.
Category:Prognostic models